Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Apr;15(4):547–553. doi: 10.1128/aac.15.4.547

Effect of Pyran on Latency After Herpes Simplex Virus Infections

Page S Morahan 1, Paul F Cline 1, Mary C Breinig 1,†, Byron K Murray 1
PMCID: PMC352709  PMID: 464586

Abstract

The immunomodulator pyran protected mice against both herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections. In infections of the lip with HSV-1, prophylactic administration of pyran reduced the severity of the herpetic lesions and enhanced their resolution, but did not decrease the high incidence of development of latent HSV-1 infection of the trigeminal ganglia. In vaginal infections with HSV-2, prophylactic administration of pyran either systemically or locally reduced mortality, reduced the incidence of mice with vaginal HSV-2 infection, and did not alter the low incidence of latent infection of the spinal dorsal root ganglia. Pyran treatment before systemic herpetic infection after intravenous inoculation of HSV-2 also reduced mortality and virus replication, as evidenced by a decreased antibody response in the survivors, and it either reduced latent infection in the spinal dorsal root ganglia or did not predispose mice to latent infection. Treatment with the immunomodulator appeared to inhibit or reduce HSV infection early in viral pathogenesis in all three model systems, producing protection from clinical disease and resulting in less virus to induce a systemic antibody response, with either a reduction in latent virus infection or no enhancement of development of latency. In all of the HSV models, the development of latent herpetic infection was closely correlated with sufficient virus replication early in the infection to induce a systemic neutralizing-antibody response.

Full text

PDF
547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. B., Hintz O. J., Wolf S. M., Huffman J. H., Simon L. N., Robins R. K., Sidwell R. W. Effect of 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate on genital lesions and encephalitis induced by Herpesvirus hominis type 2 in female mice. J Infect Dis. 1976 Jun;133 (Suppl):A178–A183. doi: 10.1093/infdis/133.supplement_2.a178. [DOI] [PubMed] [Google Scholar]
  2. Anderson F. D., Ushijima R. N., Larson C. L. Recurrent herpes genitalis. Treatment with Mycobacterium bovis (BCG). Obstet Gynecol. 1974 Jun;43(6):797–805. [PubMed] [Google Scholar]
  3. Bierman S. M. BCG immunoprophylaxis of recurrent herpes progenitalis. Arch Dermatol. 1976 Oct;112(10):1410–1415. [PubMed] [Google Scholar]
  4. Breinig M. C., Wright L. L., McGeorge M. B., Morahan P. S. Resistance to vaginal or systemic infection with herpes simplex virus type 2. Arch Virol. 1978;57(1):25–34. doi: 10.1007/BF01315634. [DOI] [PubMed] [Google Scholar]
  5. Cook M. L., Stevens J. G. Latent herpetic infections following experimental viraemia. J Gen Virol. 1976 Apr;31(1):75–80. doi: 10.1099/0022-1317-31-1-75. [DOI] [PubMed] [Google Scholar]
  6. Duff R., Rapp F. Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nat New Biol. 1971 Sep 8;233(36):48–50. doi: 10.1038/newbio233048a0. [DOI] [PubMed] [Google Scholar]
  7. Fischer G. W., Podgore J. K., Bass J. W., Kelley J. L., Kobayaski G. Y. Enhanced host defense mechanisms with levamisole in suckling rats. J Infect Dis. 1975 Nov;132(5):578–581. doi: 10.1093/infdis/132.5.578. [DOI] [PubMed] [Google Scholar]
  8. Forghani B., Klassen T., Baringer J. R. Radioimmunoassay of herpes simplex virus antibody: correlation with ganglionic infection. J Gen Virol. 1977 Sep;36(3):371–375. doi: 10.1099/0022-1317-36-3-371. [DOI] [PubMed] [Google Scholar]
  9. Hilleman M. R. Herpes simplex vaccines. Cancer Res. 1976 Feb;36(2 Pt 2):857–858. [PubMed] [Google Scholar]
  10. Kern E. R., Richards J. T., Overall J. C., Jr, Glasgow L. A. Genital Herpesvirus homonis infection in mice. II. Treatment with phosphonoacetic acid, adenine arabinoside, and adenine arabinoside 5'-monophosphate. J Infect Dis. 1977 Apr;135(4):557–567. doi: 10.1093/infdis/135.4.557. [DOI] [PubMed] [Google Scholar]
  11. Kirchner H., Hirt H. M., Munk K. Protection against herpes simplex virus infection in mice by Corynebacterium parvum. Infect Immun. 1977 Apr;16(1):9–11. doi: 10.1128/iai.16.1.9-11.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kitces E. N., Morahan P. S., Tew J. G., Murray B. K. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine. Infect Immun. 1977 Jun;16(3):955–960. doi: 10.1128/iai.16.3.955-960.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Klein R. J., Friedman-Kien A. E., Yellin P. B. Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment. Infect Immun. 1978 Apr;20(1):130–135. doi: 10.1128/iai.20.1.130-135.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McCord R. S., Breinig M. K., Morahan P. S. Antiviral effect of pyran against systemic infection of mice with herpes simplex virus type 2. Antimicrob Agents Chemother. 1976 Jul;10(1):28–33. doi: 10.1128/aac.10.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Morahan P. S., Breinig M. C., McGeorge M. B. Immune responses to vaginal or systemic infection of BALB/c mice with herpes simplex virus type 2. J Immunol. 1977 Dec;119(6):2030–2036. [PubMed] [Google Scholar]
  16. Morahan P. S., Kern E. R., Glasgow L. A. Immunomodulator-induced resistance against herpes simplex virus. Proc Soc Exp Biol Med. 1977 Apr;154(4):615–620. doi: 10.3181/00379727-154-39730. [DOI] [PubMed] [Google Scholar]
  17. Olsen G. A., Kern E. R., Overall J. C., Jr Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice. J Infect Dis. 1978 Apr;137(4):428–436. doi: 10.1093/infdis/137.4.428. [DOI] [PubMed] [Google Scholar]
  18. Overby L. R., Duff R. G., Mao J. C. Antiviral potential of phosphonoacetic acid. Ann N Y Acad Sci. 1977 Mar 4;284:310–320. doi: 10.1111/j.1749-6632.1977.tb21966.x. [DOI] [PubMed] [Google Scholar]
  19. Price R. W., Walz M. A., Wohlenberg C., Notkins A. L. Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization. Science. 1975 May 30;188(4191):938–940. doi: 10.1126/science.166432. [DOI] [PubMed] [Google Scholar]
  20. Rapp F., Reed C. Experimental evidence for the oncogenic potential of herpes simplex virus. Cancer Res. 1976 Feb;36(2 Pt 2):800–806. [PubMed] [Google Scholar]
  21. Walz M. A., Price R. W., Hayashi K., Katz B. J., Notkins A. L. Effect of immunization on acute and latent infections of vaginouterine tissue with herpes simplex virus types 1 and 2. J Infect Dis. 1977 May;135(5):744–752. doi: 10.1093/infdis/135.5.744. [DOI] [PubMed] [Google Scholar]
  22. Walz M. A., Yamamoto H., Notkins A. L. Immunological response restricts number of cells in sensory ganglia infected with herpes simplex virus. Nature. 1976 Dec 9;264(5586):554–556. doi: 10.1038/264554a0. [DOI] [PubMed] [Google Scholar]
  23. Wohlenberg C. R., Walz M. A., Notkins A. L. Efficacy of phosphonoacetic acid on herpes simplex virus infection of sensory ganglia. Infect Immun. 1976 May;13(5):1519–1521. doi: 10.1128/iai.13.5.1519-1521.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES